Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (48)

« Back to Publications

SARS-CoV-2-Specific Immune Responses to Vaccination in Children and Adolescents with Suppressed Immune Systems: A Prospective, Observational Study.

Brugha R. et al, (2026), J Pediatr, 289

Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): A randomised controlled non-inferiority trial.

Kelly E. et al, (2026), J Infect, 92

Safety, Efficacy, and Immunogenicity of a Salmonella Paratyphi A Vaccine.

McCann N. et al, (2025), N Engl J Med, 393, 1704 - 1714

Safety and immunogenicity of the invasive non-typhoidal Salmonella (iNTS)-GMMA vaccine: a first-in-human, randomised, dose escalation trial.

Hanumunthadu B. et al, (2025), EBioMedicine, 119

MAIT and other innate-like T cells integrate adaptive immune responses to modulate interval-dependent reactogenicity to mRNA vaccines.

Amini A. et al, (2025), Sci Immunol, 10

Safety and immunogenicity of an acellular pertussis vaccine containing genetically detoxified pertussis toxin administered to pregnant women living with and without HIV and their newborns (WoMANPOWER): a randomised controlled trial in Uganda.

Nakabembe E. et al, (2025), Lancet Glob Health, 13, e81 - e97

Clinical profile of paediatric acute rheumatic fever and rheumatic heart disease in Western Australia: 1987 to 2020.

Kumar M. et al, (2024), J Paediatr Child Health, 60, 375 - 383

Effects of Two Early Parenting Programmes on Child Aggression and Risk for Violence in Brazil: a Randomised Controlled Trial.

Murray J. et al, (2024), Prev Sci, 25, 834 - 848

Sex- and Age-Specific Differences in Risk Profiles and Early Outcomes in Adults With Acute Coronary Syndromes.

Nedkoff L. et al, (2024), Heart Lung Circ, 33, 332 - 341

Project publication: Two-year follow-up of infant and maternal outcomes after planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial

Chappell LC. et al, (2023), Health Technology Assessment, 27, 27 - 28

Project publication: Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial

Chappell LC. et al, (2023), Health Technology Assessment, 27, 23 - 24

Prognostic indicators of severe disease in late preterm pre-eclampsia to guide decision making on timing of delivery: the PEACOCK study

Chappell LC. et al, (2023), Health Technology Assessment, 27, 29 - 30

Cost-utility analysis of planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX)

Chappell LC. et al, (2023), Health Technology Assessment, 27, 25 - 26

Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial.

Kelly E. et al, (2023), J Infect, 87, 230 - 241

Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.

Shaw RH. et al, (2023), J Infect, 86, 574 - 583

Load More